The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Advanced Glycation End Products-driven Angiogenesis in Vitro
Open accessAbstract
This study was undertaken to determine whether and how advanced glycation end products (AGE), senescent macroproteins accumulated in various tissues under hyperglycemic states, cause angiogenesis, the principal vascular derangement in diabetic microangiopathy. We first prepared AGE-bovine serum albumin (BSA) and anti-AGE antiserum using AGE-RNase A. Then AGE-BSA was administered to human skin microvascular endothelial cells in culture, and their growth was examined. The AGE-BSA, but not nonglycated BSA, was found to induce a statistically significant increase in the number of viable endothelial cells as well as their synthesis of DNA. The increase in DNA synthesis by AGE-BSA was abolished by anti-AGE antibodies. AGE-BSA also stimulated the tube formation of endothelial cells on Matrigel. We obtained the following evidence that it is vascular endothelial growth factor (VEGF) that mainly mediates the angiogenic activities of AGE. (1) Quantitative reverse transcription-polymerase chain reaction analysis of poly(A)+ RNA from microvascular endothelial cells revealed that AGE-BSA up-regulated the levels of mRNAs for the secretory forms of VEGF in time- and dose-dependent manners, while endothelial cell expression of the genes encoding the two VEGF receptors, kinase insert domain-containing receptor and fms-like tyrosine kinase 1, remained unchanged by the AGE treatment. Immunoprecipitation analysis revealed that AGE-BSA did increase de novo synthesis of VEGF. (2) Monoclonal antibody against human VEGF completely neutralized both the AGE-induced DNA synthesis and tube formation of the endothelial cells. The results suggest that AGE can elicit angiogenesis through the induction of autocrine vascular VEGF, thereby playing an active part in the development and progression of diabetic microangiopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,751
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Folkman, J., & Shing, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49853-0 · Cited by 2,654
Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
Flier, J. S., Underhill, L. H., Brownlee, M., Cerami, A., & Vlassara, H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805193182007 · Cited by 2,511
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., & Alitalo, K. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00359.x · Cited by 1,672
Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins
FERRARA, N., HOUCK, K., JAKEMAN, L., & LEUNG, D. W. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-18 · Cited by 1,655
Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., Elliston, K., Stern, D., & Shaw, A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42138-2 · Cited by 1,541
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., & Böhlen, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90483-2 · Cited by 1,519
Cited by
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14002 · Cited by 1,253
Seghezzi, G., Patel, S., Ren, C. J., Gualandris, A., Pintucci, G., Robbins, E. S., Shapiro, R. L., Galloway, A. C., Rifkin, D. B., & Mignatti, P. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1659 · Cited by 860
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
YONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Self-citationWendt, T. M., Tanji, N., Guo, J., Kislinger, T. R., Qu, W., Lu, Y., Bucciarelli, L. G., Rong, L. L., Moser, B., Markowitz, G. S., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63909-0 · Cited by 600
Diabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
Bierhaus, A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00233-2 · Cited by 555
van Beijnum, J. R., Buurman, W. A., & Griffioen, A. W. (2008) · Angiogenesis · doi:10.1007/s10456-008-9093-5 · Cited by 527
Progranulin is a mediator of the wound response
He, Z., Ong, C. H. P., Halper, J., & Bateman, A. (2003) · Nature Medicine · doi:10.1038/nm816 · Cited by 490
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S.-I., Sakurai, S., Takasawa, S., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11771 · Cited by 475
Self-citationTanaka, N., Yonekura, H., Yamagishi, S.-I., Fujimori, H., Yamamoto, Y., & Yamamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001235200 · Cited by 424
Self-citationAdvanced glycation end products increase retinal vascular endothelial growth factor expression.
Lu, M., Kuroki, M., Amano, S., Tolentino, M., Keough, K., Kim, I., Bucala, R., & Adamis, A. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1277 · Cited by 423
Hyperglycemia and Glycation in Diabetic Complications
Negre-Salvayre, A., Salvayre, R., Augé, N., Pamplona, R., & Portero-Otín, M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2484 · Cited by 421
In Vitro Models of Vasculogenesis and Angiogenesis
Vailhé, B., Vittet, D., & Feige, J.-J. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780252 · Cited by 357
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Yamagishi, S.-I., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., Takeuchi, M., & Makita, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202634200 · Cited by 310
Self-citationPrevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: Epidemiology
Howard, B. V., Rodriguez, B. L., Bennett, P. H., Harris, M. I., Hamman, R., Kuller, L. H., Pearson, T. A., & Wylie-Rosett, J. (2002) · Circulation · doi:10.1161/01.cir.0000013953.41667.09 · Cited by 308
Advanced glycation: an important pathological event in diabetic and age related ocular disease
STITT, A. W. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.6.746 · Cited by 306
Yamagishi, S.-I. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.007 · Cited by 302
Self-citationYamagishi, S.-I., Maeda, S., Matsui, T., Ueda, S., Fukami, K., & Okuda, S. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.03.014 · Cited by 294
Self-citationCaldwell, R. B., Bartoli, M., Behzadian, M. A., El‐Remessy, A. E. B., Al‐Shabrawey, M., Platt, D. H., & Caldwell, R. W. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.415 · Cited by 293
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin
Okamoto, T., Yamagishi, S., Inagaki, Y., Amano, S., Koga, K., Abe, R., Takeuchi, M., Ohno, S., Yoshimura, A., & Makita, Z. (2002) · The FASEB Journal · doi:10.1096/fj.02-0030fje · Cited by 258
Self-citationIshihara, K., Tsutsumi, K., Kawane, S., Nakajima, M., & Kasaoka, T. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00846-9 · Cited by 201
Regulation of Vascular Endothelial Growth Factor Expression by Advanced Glycation End Products
Treins, C., Giorgetti-Peraldi, S., Murdaca, J., & Van Obberghen, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106534200 · Cited by 191
The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases
Senatus, L. M., & Schmidt, A. M. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00187 · Cited by 167
Ojima, A., Ishibashi, Y., Matsui, T., Maeda, S., Nishino, Y., Takeuchi, M., Fukami, K., & Yamagishi, S.-I. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.09.016 · Cited by 156
Self-citationZhou, J., Cai, B., Jang, Y. P., Pachydaki, S., Schmidt, A. M., & Sparrow, J. R. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2004.11.009 · Cited by 113
Rojas, A., Añazco, C., González, I., & Araya, P. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy012 · Cited by 82
Advanced Glycation End Products Induce Angiogenesis in Vivo
Okamoto, T., Tanaka, S., Stan, A. C., Koike, T., Kase, M., Makita, Z., Sawa, H., & Nagashima, K. (2002) · Microvascular Research · doi:10.1006/mvre.2001.2371 · Cited by 47
Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells
Yamamoto, Y., Yonekura, H., Watanabe, T., Sakurai, S., Li, H., Harashima, A., Myint, K. M., Osawa, M., Takeuchi, A., Takeuchi, M., et al. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.030 · Cited by 44
Self-citationCathelicidin Modulates Vascular Smooth Muscle Cell Phenotypic Switching through ROS/IL-6 Pathway
Dong, X., Wu, D., Zhang, Y., Jia, L., Pan, X., Sun, J., & Pan, L.-L. (2020) · Antioxidants · doi:10.3390/antiox9060491 · Cited by 25
Saito, R., Araki, S., Yamamoto, Y., & Kusuhara, K. (2017) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0262 · Cited by 8
Self-citation
Metadata
- Authors
- Yamagishi, S.-I., Yonekura, H., Yamamoto, Y., Katsuno, K., Sato, F., Mita, I., Ooka, H., Satozawa, N., Kawakami, T., Nomura, M., & Yamamoto, H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-03
- Volume
- 272
- Issue
- 13
- Pages
- 8723-8730
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2145922680
- Cited by
- 276
- References
- 44
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.